On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development. Additional links to TB R&D are included.
In this week’s article, potential cellular biomarkers are explored in the mouse model with three potential markers: PD-1 and TIM-3 on CD8 T cells and KIRG-1 on both CD4 and CD8 T cells. The search for validated biomarkers that can predict treatment success has been a difficult one. The focus of much of the research on biomarkers has been on serum markers, because of practical reasons and considerations of use in resource-limited settings. Henao-Tamayo, et al., took a different focus looking at markers on the surface of lung T cells. Additional links to TB R&D News are included.
This week, we feature an interview with Dr. Edward Nardell who is a pulmonologist with a special interest in tuberculosis. His principal academic appointment is as associate professor of medicine, Harvard Medical School. In 2002 he joined Partners In Health as Director of Tuberculosis Research. During the interview, we discuss with Dr. Nardell his background and interest in TB, the Airbourne Infections Research (AIR) Facility, his thoughts on the MDR-TB epidemic, and his current research focus. Additional links to TB R&D News are included.
The WGND had the opportunity to interview three researchers (Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma) involved in the groundbreaking research on the role of efflux pumps in contributing to drug tolerance during TB treatment which was published in the April 1 issue of Cell. Additional links to TB R&D News are included.
In this week”s TB R&D update, the WGND had the opportunity to talk with Dr. Nuermberger on a recent article entitled “PA-824 exhibits time-dependent activity in a murine model of tuberculosis” that we covered in a previous TB R&D Weekly Update. In the interview, Dr. Nuermberger provides an overview of his present research, key results presented in the article, and in vitro and preclinical testing of TB drug regimens. Also, links to additional news in TB R&D are included.
In this week”s TB R&D update, the WGND had the opportunity to talk with Dr. Lenaerts on a recent article published ahead of print in the Antimicrobial Agents and Chemotherapy journal in December 2010. Dr. Anne Lenaerts is an associate professor at Colorado State University”s College of Veterinary Medicine and Biomedical Sciences in the Department of Microbiology, Immunology and Pathology. In the interview, Dr. Lenaerts provides an overview of her present research and the article, key recommendations for use of mouse models for testing TB drugs and the issue of relapse studies. Also, links to additional news in TB R&D are included.